Ranibizumab safety in pregnancy
1 December 2018
| Sofia Rokerya
|
EYE - Vitreo-Retinal
Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...
OCTA and pigment epithelium detachments
1 December 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
Yannuzzi et al. report on their study aiming to evaluate the ability of optical coherence tomography angiography (OCTA) to differentiate vascularised from nonvascularised pigment epithelium detachments (PEDs) using conventional imaging techniques, including fundus fluorescein angiography (FFA) and indocyanine green (ICG),...
2018 update on intravitreal injections
1 December 2018
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this review article the authors have highlighted the standardised and structured approach to intravitreal injections (IVI) by examining the recent evidence-based literature. IVI is the most commonly performed procedure worldwide with low potential risk of endophthalmitis. IOP spikes are...
Incidence and risk factors of ocular hypertension following PPV and SOI
1 December 2018
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this prospective, interventional study the authors evaluated the risk factors for elevated intraocular pressure (IOP) after pars plana vitrectomy (PPV) with silicone oil injection (SOI). This study included 254 eyes of 254 patients, with a mean age of 55.33...
Reduction of severe visual loss and complications following IAC for RB
1 October 2018
| Jonathan Chan
|
EYE - Vitreo-Retinal
This was a retrospective cohort study of patients with retinoblastoma (RB) who required intra-arterial chemotherapy (IAC) between 2013 and 2015, who had relapsed following systemic chemotherapy. A total of nine patients were included in the study and their ocular complications...
PRN Ranibizumab verses continuous aflibercept in UK clinical practice
1 October 2018
| Jonathan Chan
|
EYE - Vitreo-Retinal
This was a multicentre (21 UK hospitals), national EMR study on treatment naïve nAMD eyes, undergoing predominantly as needed (PRN) Ranibizumab or continuous (fixed or treat and extend - (F/TE)) Aflibercept (Af). The primary outcome was change in vision at...
Correlation between anti-retinal antibodies and proliferative vitreoretinopathy (PVR)
1 October 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
The pathological basis of PVR is not clearly understood and there are no effective medications targeting this condition. This cross-sectional study looked at the possible association of anti-retinal antibodies with patients with PVR and retinal detachment (RD). Aqueous and vitreous...
Macular atrophy with aflibercept
1 October 2018
| Saruban Pasu
|
EYE - Vitreo-Retinal
The authors of this paper set out to investigate the prevalence of macular atrophy in treatment-naive patients with neovascular AMD undergoing aflibercept monotherapy (three monthly loading injections followed by subsequent treatment every two months). Case notes over a three year...
Meta-analysis of HLA B27 associated acute anterior uveitis
1 August 2018
| Mrinal Rana
|
EYE - Vitreo-Retinal
A literature-based meta-analysis was carried out to look at the various clinical features associated with HLA- B27 acute anterior uveitis (AAU). After an extensive search of literature for HLA B27 uveitis was conducted, 735 results were obtained. Twenty-nine articles were...
Automated grading of diabetic retinopathy: is it possible?
1 August 2018
| Eulee Seow
|
EYE - Vitreo-Retinal
Diabetic retinopathy (DR) is a frequent microvascular complication of diabetes and a leading cause of blindness worldwide. However, much of this diabetic blindness can be delayed or even prevented with timely diagnosis and proper treatment. For this reason, regular screening...
International variations in ROP treatment
1 August 2018
| Jonathan Chan
|
EYE - Vitreo-Retinal
A retrospective cohort review of 48,087 premature infants weighing <1500 gm between 24 to 27 weeks gestation, from 11 high income countries in Australia, New Zealand, Canada, Finland, Israel, Japan, Spain, Sweden, Switzerland, Tuscany (Italy) and the UK . By...
The effect of everolimus on retinal pigment epithelium and proliferative vitreo-retinopathy
1 August 2018
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
The principal cells involved in proliferative vitreo-retinopathy (PVR) are retinal pigment epithelial cells (RPE). Everolimus is a drug used in renal cell carcinoma which targets and inhibits a key regulatory protein in cancer (mTOR). In this study, the authors investigated...
